Research Project

Project Title:	A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF NEFECON IN PATIENTS WITH PRIMARY IGA NEPHROPATHY AT RISK OF PROGRESSING TO END-STAGE RENAL DISEASE (NefIgArd)
Project Type:	Clinical Trial, Enrolment terminated
Disease group(s):	Immune glomerulopathies
Project Summary:	The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN at risk of progressing to end-stage renal disease (ESRD), despite maximum tolerated treatment with renin-angiotensin system (RAS) blockade using angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs)
Lead principal investigator(s):	Loreto Gesualdo, Bari
Co-investigator(s):	S Cuna, Bari F Annese, Bari
Project Period:	07/2019 - 07/2023
Sponsors:	Industry
EudraCT Nr.:	2017-004902-16